Amylyx Pharmaceuticals, Inc.

AMLX Nasdaq SEC CIK 1658551
Follow Amylyx Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$45.5M −32.3% vs same quarter last year
EPS, diluted −$0.38 −2.7% vs same quarter last year
Operating cash flow −$33.7M −10.9% vs same quarter last year
Operating income −$49.7M −37.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$144.7M
FY24$87.4M−$301.7M
FY23$380.8M$49.3M
FY22$22.2M−$198.4M
FY21$285K−$87.9M
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY2493.2%−360.2%−345.4%
FY2393.3%10.2%12.9%
FY2286.5%−905.7%−892.4%
FY21-−29013.3%−30853%
FY20---
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0$50MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$123.5M
FY24−$167.8M
FY23$10.7M
FY22−$182.4M
FY21−$75.2M
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Amylyx Pharmaceuticals
  • Healthcare median
−40000%−30000%−20000%−10000%0%10000%FY20FY21FY22FY23FY24FY25
Show the numbers
YearAmylyx PharmaceuticalsHealthcare median
FY25-−30.6%
FY24−345.4%−47%
FY2312.9%−58%
FY22−892.4%−80.4%
FY21−30853%−71.9%
FY20-−62.2%